Quick Facts

• Condition Focus: Certain types of fast, irregular heart rhythms (arrhythmias).
• Main Goal: Supporting a consistent heart rhythm.
• Primary Uses: Managing conditions such as paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation/flutter (PAF).

---

What Flecainidacetat STADA Treats: Main Uses and Benefits

Flecainidacetat STADA is a prescription medication utilized to address and manage specific types of abnormal heart rhythms, known as arrhythmias. The medication is used primarily when these irregular heartbeats are causing significant symptoms or are considered life-threatening conditions.

It is applied for the management of supraventricular arrhythmias, which are fast, irregular heart rhythms originating in the upper chambers of the heart. This includes use in individuals with paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation/flutter (PAF).

Additionally, this drug is an option for helping to prevent certain life-threatening ventricular arrhythmias—irregular heart rhythms originating in the lower chambers of the heart, such as sustained ventricular tachycardia. The core therapeutic benefit is to support the heart's electrical system, which may help to promote a more consistent heart rhythm. Its use is generally restricted to patients where the benefits are considered to outweigh the potential risks and should be undertaken under careful medical supervision.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Map: Official Regulatory Information

The eligibility profile for Flecainidacetat STADA is defined by strict regulatory criteria, primarily prohibiting use in populations with pre-existing heart disease due to increased risk.

Classification	Population Restriction
Contraindicated	Patients with pre-existing second- or third-degree AV block or bifascicular block who do not have a pacemaker [Source 1.4, 2.2].
Contraindicated	Patients with structural heart disease, abnormal left ventricular function (e.g., severe heart failure), cardiogenic shock, or a recent myocardial infarction [Source 1.4, 2.1].
Contraindicated	Individuals with known hypersensitivity to Flecainide Acetate [Source 1.4].
Not Recommended	Children under 12 years of age; safety and efficacy are not established in this age group [Source 1.2, 2.1].

Conditional Use Requirements:

Use is restricted for certain groups where the body's ability to clear the medicine is reduced. Patients with significant hepatic or renal impairment may require close monitoring due to potential for reduced drug clearance [Source 1.4, 2.1]. Additionally, any existing electrolyte imbalance must be corrected before treatment is initiated [Source 1.4]. The use during pregnancy is generally not recommended unless the benefit outweighs the potential risks [Source 2.1].

Official regulatory documents establish these clear restrictions to define who may be considered for the medicine and who is formally excluded.

Interactions with other medicines and products

The interaction profile of Flecainidacetat STADA is officially defined by its metabolic clearance pathway and potential for additive cardiac effects. The most clinically significant interactions are generally classified as major or contraindicated in regulatory documents.

Contraindicated and High-Risk Combinations

Co-administration is contraindicated with certain Class III antiarrhythmics, such as Dronedarone, and with agents known to prolong the QTc interval, including Pimozide and Thioridazine. Other Class I antiarrhythmics must not be administered concurrently due to the documented risk of additive effects.

Pharmacokinetic and Exposure Modification

Interactions involving the CYP2D6 enzyme system are officially documented. Strong inhibitors of this system, such as Amiodarone, significantly reduce the clearance of Flecainide Acetate, resulting in the potential for two-fold or more increases in plasma concentrations. The histamine H2 receptor antagonist, Cimetidine, also increases Flecainide exposure by reducing its clearance.

Pharmacodynamic and Substance Effects

Coadministration with Beta-blockers carries the documented risk of additive negative inotropic effects on heart function. Additionally, substances that alter urinary pH, such as alkalinizing agents, can reduce the renal excretion of Flecainide Acetate, prolonging the half-life and increasing systemic exposure. Regulatory information also notes that the use of milk or milk-containing products may inhibit oral absorption in infants and children.

Mechanism of Action: Cardiac Electrophysiology

Flecainide's primary action involves the inhibition of the cardiac sodium channel (Nav1.5) in atrial, ventricular, and Purkinje cells. This interaction blocks the rapid, inward flux of sodium ions ( Na^+) necessary for the initial depolarization (Phase 0) of the cardiac action potential. The blockade is use-dependent, increasing in intensity as the frequency of channel activation rises.

This molecular inhibition results in a significant reduction in the maximum rate of depolarization, which translates into a decrease in the conduction velocity of the electrical impulse throughout the heart muscle. Additionally, it prolongs the effective refractory period (ERP), the recovery time required by the tissue before it can transmit a new impulse. These changes in conduction and refractoriness modulate the electrical transmission pathways, disrupting the conditions necessary for self-sustaining electrical circuits. This mechanism may also lead to a decrease in the force of myocardial contraction (negative inotropy), a secondary physiological consequence of altered ion dynamics.

How to Use Flecainidacetat STADA: Administration Overview

Flecainidacetat STADA, containing the active substance Flecainide Acetate, is administered according to specific patterns. The medication is primarily available for oral administration in tablet form for long-term management. An intravenous (IV) solution is also available, typically reserved for rapid, acute control in monitored settings.

Standard Dosing and Schedule

Oral treatment is generally taken twice daily to maintain consistent concentrations. The standard starting dose for supraventricular conditions is often 50 mg twice daily, with the dosage then adjusted in increments of 50 mg twice daily. Dose adjustments are typically made no more often than every four days to allow for the attainment of steady-state plasma concentrations. The maximum oral dose can range up to 300 mg per day for supraventricular arrhythmias and up to 400 mg per day for life-threatening ventricular arrhythmias.

Flecainidacetat STADA tablets may be taken with or without food. If a dose is missed, the standard protocol is to take the dose as soon as possible, while strictly avoiding doubling the dose if it is almost time for the next scheduled dose.

Population-Specific Constraints

The initial daily dose is constrained for certain groups. For older adults and patients with severe renal or hepatic impairment, the starting dose is typically limited to 100 mg per day (50 mg twice daily). The use of the medication in such populations involves careful observation and often includes the monitoring of drug plasma levels.

The research evidence for Flecainide Acetate is gathered from various types of clinical studies, primarily focusing on studies exploring how the compound was evaluated in the heart's electrical system. The evidence applies specifically to highly selected groups of patients; the limitations and constraints define the nature of the research base.

Research Evidence for Paroxysmal Supraventricular Arrhythmias

Clinical evidence, primarily based on randomized controlled trials (RCTs) and systematic reviews, examined changes in cardiac rhythm status (restoration and maintenance) in adults with intermittent fast heart rhythms (AF/flutter and PSVT). Studies monitored populations enrolled on the condition that they had no underlying structural heart disease. Findings describe patterns observed in the studies related to the maintenance of the studied rhythm state. Long-term effects are not fully established; certainty remains low for outcomes extending beyond the medium-term follow-up observed in the primary RCTs.

Research Evidence for Severe Ventricular Arrhythmias

Research for life-threatening sustained ventricular tachycardia (VT) stems from early trials and regulatory studies. These studies focused on monitoring the rate of sustained VT episodes in select adult patients who were free of any significant structural heart disease. Findings describe patterns observed related to the rate of reduction of ventricular beats. Follow-up durations were limited, reflecting the constraints on patient inclusion.

Research Evidence for High Burden of Premature Ventricular Contractions (PVCs)

This research uses smaller trials and observational cohorts, which primarily measured the reduction rate of PVCs over 24 hours. Findings were mixed in some studies regarding improvement in outcomes related to physical discomfort. The research base is characterized by modest sample sizes, and the long-term clinical significance of PVC reduction is not fully established.

Key Constraints and Evidence Gaps

Findings indicate that the results apply only to the populations studied—specifically, individuals without underlying structural heart disease. The evidence describes that the compound was associated with patterns of observed outcomes in historical research involving patients who had underlying heart conditions. Data for certain groups remain insufficient, and comparative evidence is lacking against newer therapeutic options that have been developed.

Key Studies & References

1. Flecainide acetate (NIH MedlinePlus Drug Information)

Common questions about Flecainidacetat STADA (FAQ)

Q: What is Flecainidacetat STADA used for?

Flecainidacetat STADA contains flecainide, which is used to treat certain types of abnormal heart rhythms (cardiac arrhythmias). Specifically, it helps to restore a normal heart rhythm and maintain a regular heartbeat in people with specific, serious rhythm disturbances.

Q: How does Flecainidacetat STADA work?

Flecainide is an antiarrhythmic medicine belonging to the class IC group. It works by affecting the movement of sodium ions in the heart muscle cells. This action slows down the electrical signals in the heart, helping to stabilize the heart's rhythm and preventing the chaotic electrical activity that causes arrhythmias.

Q: Who should not take Flecainidacetat STADA?

Flecainidacetat STADA is not suitable for everyone. You should not take it if you have certain pre-existing heart conditions, such as:

• Severe heart failure
• Certain structural heart diseases
• Recent heart attack
• Specific types of heart block (unless a pacemaker is present) Always inform your doctor about your complete medical history, especially any heart or kidney problems, before starting this medication.

Q: What are the common side effects of Flecainidacetat STADA?

Common side effects may include:

• Dizziness or lightheadedness
• Visual disturbances (such as blurred vision)
• Nausea or vomiting
• Shortness of breath These side effects are often mild and may improve as your body adjusts. If any side effect becomes severe or persistent, contact your doctor or pharmacist.

Q: Can Flecainidacetat STADA interact with other medicines?

Yes, flecainide can interact with many other medicines, which can change how flecainide or the other medicines work. It is essential to tell your doctor or pharmacist about all prescription, over-the-counter, and herbal products you are taking. Examples of interacting medicines include:

• Other antiarrhythmics
• Certain beta-blockers
• Cimetidine (an antacid)
• Quinidine

How to Store and Dispose of Flecainidacetat STADA

Official regulatory labeling specifies the required conditions for storing and disposing of Flecainide Acetate tablets.

Storage Requirements

The product does not require any special storage conditions regarding temperature or environment. The tablets must be kept in their original container to ensure stability throughout the labeled shelf-life, which is typically 36 months or 4 years.

Child Safety Requirement:

• The medicine must be strictly kept out of the sight and reach of children.

Disposal Instructions

When the product is expired or unused, it must not be disposed of via household waste or wastewater. Official instructions mandate that any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.